(Q38274609)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444021%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

review article

1 reference

title

Checkpoint immunotherapy for cancer: superior survival, unaccustomed toxicities (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444021%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444021%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Thomas John

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444021%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

A van der Westhuizen

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444021%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

publication date

1 July 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444021%20AND%20SRC:MED&resulttype=core&format=json

Internal Medicine Journal

23 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444021%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

45

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444021%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444021%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

696-701

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444021%20AND%20SRC:MED&resulttype=core&format=json

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

23 February 2020

cites work

1 reference

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4.

21 January 2018

1 reference

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

21 January 2018

1 reference

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

21 January 2018

1 reference

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

21 January 2018

1 reference

Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab

21 January 2018

1 reference

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

21 January 2018

1 reference

Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis

21 January 2018

1 reference

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/IMJ.12653

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444021%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference